Literature DB >> 30811824

Brca2 abrogation engages with the alternative lengthening of telomeres via break-induced replication.

Mi-Sun Kwon1, Jennifer J Lee1, Jaewon Min1, Kwangwoo Hwang1, Seung Gu Park2, Eun-Hye Kim2, Byung Chul Kim3, Jong Bhak2,3, Hyunsook Lee1.   

Abstract

A subset of cancer cells maintains their telomeres without telomerase through the recombination-based alternative lengthening of telomeres (ALT) pathway. Currently, it is not yet clear in what context ALT is induced and how the pathway choice is made. Here, we show that abrogation of Brca2 reinforces break-induced replication (BIR) and engages with ALT pathway. Brca2 depletion in telomerase-null mouse cells alleviated the growth defect, accompanied by telomere elongation, suggesting the induction of ALT. We also found that Brca2-depleted telomerase-null cells exhibited dynamic clustering of telomeres from G2 phase in Promyelocytic Nuclear (PML) bodies. For Brca2-deficient ALT induction, Rad51 was dispensable but Mre11 and Rad52 were required. Congruently, conservative telomeric DNA synthesis was apparent in mitosis, indicating that the absence of Brca2 directed towards Rad52-mediated BIR. Collectively, we propose that Brca2 abrogation can instigate ALT tumourigenesis through the induction of BIR. This study implies that inhibitors of BIR may be useful for BRCA2-associated ALT-type cancers. Assessing ALT features may be considered for the tailored therapy of BRCA2-associated cancers.
© 2019 Federation of European Biochemical Societies.

Entities:  

Keywords:  ALT mouse; Brca2; alternative lengthening of telomeres; break-induced replication

Mesh:

Substances:

Year:  2019        PMID: 30811824     DOI: 10.1111/febs.14796

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  7 in total

1.  Dynamic interaction of BRCA2 with telomeric G-quadruplexes underlies telomere replication homeostasis.

Authors:  Junyeop Lee; Keewon Sung; So Young Joo; Jun-Hyeon Jeong; Seong Keun Kim; Hyunsook Lee
Journal:  Nat Commun       Date:  2022-06-13       Impact factor: 17.694

2.  XAB2 promotes Ku eviction from single-ended DNA double-strand breaks independently of the ATM kinase.

Authors:  Abhishek Bharadwaj Sharma; Hélène Erasimus; Lia Pinto; Marie-Christine Caron; Diyavarshini Gopaul; Thibaut Peterlini; Katrin Neumann; Petr V Nazarov; Sabrina Fritah; Barbara Klink; Christel C Herold-Mende; Simone P Niclou; Philippe Pasero; Patrick Calsou; Jean-Yves Masson; Sébastien Britton; Eric Van Dyck
Journal:  Nucleic Acids Res       Date:  2021-09-27       Impact factor: 16.971

3.  BRCA2 Deletion Induces Alternative Lengthening of Telomeres in Telomerase Positive Colon Cancer Cells.

Authors:  Luca Pompili; Carmen Maresca; Angela Dello Stritto; Annamaria Biroccio; Erica Salvati
Journal:  Genes (Basel)       Date:  2019-09-10       Impact factor: 4.096

4.  ATRX proximal protein associations boast roles beyond histone deposition.

Authors:  William A Scott; Erum Z Dhanji; Boris J A Dyakov; Ema S Dreseris; Jonathon S Asa; Laura J Grange; Mila Mirceta; Christopher E Pearson; Grant S Stewart; Anne-Claude Gingras; Eric I Campos
Journal:  PLoS Genet       Date:  2021-11-15       Impact factor: 6.020

Review 5.  Regulation of Replication Stress in Alternative Lengthening of Telomeres by Fanconi Anaemia Protein.

Authors:  Duda Li; Kailong Hou; Ke Zhang; Shuting Jia
Journal:  Genes (Basel)       Date:  2022-01-20       Impact factor: 4.096

6.  XRCC1 promotes replication restart, nascent fork degradation and mutagenic DNA repair in BRCA2-deficient cells.

Authors:  Bradley J Eckelmann; Albino Bacolla; Haibo Wang; Zu Ye; Erika N Guerrero; Wei Jiang; Randa El-Zein; Muralidhar L Hegde; Alan E Tomkinson; John A Tainer; Sankar Mitra
Journal:  NAR Cancer       Date:  2020-08-01

7.  BRCA2 Haploinsufficiency in Telomere Maintenance.

Authors:  Soffía R Gunnarsdottir; Hördur Bjarnason; Birna Thorvaldsdottir; Felice Paland; Margrét Steinarsdottir; Jórunn E Eyfjörd; Sigrídur K Bödvarsdottir
Journal:  Genes (Basel)       Date:  2021-12-28       Impact factor: 4.096

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.